1. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012; 12:204.
![crossref](/image/icon/bnr_ref_cross.gif)
2. Su N, Lin J, Liu G, Chen P, Zhou X, Wan H, et al. An epidemiological survey of current asthma control status in China. Zhonghua Nei Ke Za Zhi. 2014; 53:601–606.
3. Global Strategy for Asthma Management and Prevention. 2018 Global initiative for asthma [Internet]. Fontana (WI): Global Initiative for Asthma;2018. cited 2019 Jan 30. Available from:
http://ginasthma.org/.
4. Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med. 2006; 100:1307–1317.
![crossref](/image/icon/bnr_ref_cross.gif)
5. Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010; 363:1715–1726.
6. Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol. 2011; 128:315–322.
![crossref](/image/icon/bnr_ref_cross.gif)
7. Kerstjens HA, Disse B, Schröder-Babo W, Bantje TA, Gahlemann M, Sigmund R, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol. 2011; 128:308–314.
8. Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012; 367:1198–1207.
![crossref](/image/icon/bnr_ref_cross.gif)
9. Paggiaro P, Halpin DM, Buhl R, Engel M, Zubek VB, Blahova Z, et al. The effect of tiotropium in symptomatic asthma despite low- to medium-dose inhaled corticosteroids: a randomized controlled trial. J Allergy Clin Immunol Pract. 2016; 4:104–113.e2.
![crossref](/image/icon/bnr_ref_cross.gif)
10. Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016; CD011721.
![crossref](/image/icon/bnr_ref_cross.gif)
11. Kerstjens HA, Casale TB, Bleecker ER, Meltzer EO, Pizzichini E, Schmidt O, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med. 2015; 3:367–376.
12. Rhee H, Love T, Mammen J. Comparing Asthma Control Questionnaire (ACQ) and National Asthma Education and Prevention Program (NAEPP) asthma control criteria. Ann Allergy Asthma Immunol. 2019; 122:58–64.
![crossref](/image/icon/bnr_ref_cross.gif)
13. Bateman ED, Esser D, Chirila C, Fernandez M, Fowler A, Moroni-Zentgraf P, et al. Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: Systematic review and network meta-analysis. J Allergy Clin Immunol. 2015; 136:914–922.
![crossref](/image/icon/bnr_ref_cross.gif)
14. Aalbers R, Park HS. Positioning of long-acting muscarinic antagonists in the management of asthma. Allergy Asthma Immunol Res. 2017; 9:386–393.
![crossref](/image/icon/bnr_ref_cross.gif)
15. Halpin DM, Kaplan AG, Russell RK. Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators. Respir Med. 2017; 128:28–41.
![crossref](/image/icon/bnr_ref_cross.gif)
16. Buhl R, FitzGerald JM, Busse WW. Tiotropium add-on to inhaled corticosteroids versus addition of long-acting β2-agonists for adults with asthma. Respir Med. 2018; 143:82–90.